Expert Analysis

CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 07, 2020

Expiration: August 06, 2021

Axel Grothey
Axel Grothey, MD
Manish A. Shah
Manish A. Shah, MD

Activity

Progress
1
Course Completed

In this activity, Axel Grothey, MD, and Manish A. Shah, MD, review key gastrointestinal (GI) cancer studies presented at the 2020 ASCO Virtual Scientific Meeting, focusing on new data surrounding the treatment of colorectal, gastroesophageal, and pancreatic cancers.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with GI cancers do you provide care for in a typical month?

A colleague has used immune checkpoint inhibitors to treat patients with metastatic microsatellite instability–high (MSI-H) colorectal cancer (CRC) in later-line settings and asks you if you are aware of any data with these agents in the first-line setting.

Which of the following findings was reported with first-line pembrolizumab vs standard-of-care chemotherapy in patients with metastatic, MSI-H/mismatch repair–deficient (dMMR) CRC in the phase III KEYNOTE-177 trial?

Which of the following findings was reported with trastuzumab deruxtecan (T-DXd) vs standard-of-care chemotherapy in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer in the randomized phase II DESTINY-Gastric01 trial?

A 66-year-old man with stage T3N0 esophageal adenocarcinoma arrives at your clinic. Biomarker testing reveals a HER2-positive tumor (IHC 3+); the surgical team determines that he is a candidate for potential curative resection.

How likely would you be to recommend perioperative trastuzumab in addition to preoperative chemoradiotherapy and surgery for this patient?

Please rate your likelihood on a scale of 1 to 7.